Pfizer Independent Medical Education Grant Request for Proposals: Current and Emerging Therapies for Recurrent or Metastatic Cervical Cancer
Pfizer Inc. funds educational projects to advance clinician knowledge of current and emerging therapies for recurrent or metastatic cervical cancer, focusing on translating new science into community oncology practice.
Funder: Pfizer Inc.
Due Dates: September 24, 2026: Submission Deadline
Funding Amounts: Typical awards range from $50,000–$250,000; total available budget is $250,000; max project duration is 1 year.
Summary: Supports innovative educational initiatives to improve clinician knowledge and care in recurrent or metastatic cervical cancer, with emphasis on new therapies and community oncology education.
Key Information: Late applications will not be reviewed; only organizations (not individuals) are eligible.
Description
This grant opportunity from Pfizer Inc. seeks to fund independent medical education projects that address the evolving treatment landscape for recurrent or metastatic (r/m) cervical cancer. The aim is to enhance the knowledge, confidence, and competence of clinicians and care teams—especially those in community settings—regarding current and emerging therapies, including targeted therapies, post-IO progression, antibody-drug conjugates, management of adverse events, and long-term outcomes. Eligible projects can include conference sessions, workshops, tumor boards, digital toolkits, and enduring online materials, all focused on advancing community-based oncology care.
